Clinical outcomes of dry-preserved amniotic membrane allograft transplant for ocular surface disease - DAMAT for OSD

Peregrine Eye and Laser Institute Research Section0 sites30 target enrollmentMay 9, 2021

ConditionsOcular suface disease

Overview

Phase: Phase 4
Intervention: Not specified
Conditions: Ocular suface disease
Sponsor: Peregrine Eye and Laser Institute Research Section
Enrollment: 30
Status: Completed
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

Improved ocular comfort was reported 97%. Mean ocular discomfort score decreased from 3.30 to 1.24 while mean photophobia score decreased from 3.15 to 1.27. Mean LogMAR BCVA improved from 0.42 to 0.25. The AM and SCL remained in position for 94% of eyes. Complete corneal epithelialization was observed in all eyes immediately after SCL removal.

Registry

who.int

Start Date

May 9, 2021

End Date

July 15, 2018

Last Updated

2 years ago

Study Type

Interventional

Sex

All

Investigators

Sponsor

Peregrine Eye and Laser Institute Research Section

Eligibility Criteria

Inclusion Criteria

Not provided

Exclusion Criteria

•Subjects were excluded from the study if any of the following criteria was fulfilled, corneal or scleral perforation or impending perforation, subjects with recent or active infection, subjects not able to understand the character and individual consequences of the investigation, and participation in other clinical research within the last 8 weeks.